An Evaluation of VYC ‐17. 5L for Forehead Contouring: A Prospective, Open‐Label, Post‐Marketing Study
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.70093 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Sofia Ruiz Del Cueto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clínica Mira and Cueto, Madrid, Spain. Hauptthemen laut MEDLINE: Cosmetic Techniques, Dermal Fillers, Hyaluronic Acid, Lidocaine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Background
Forehead contouring can be achieved using injectable fillers. VYC‐17.5L is a filler containing 17.5 mg/mL of hyaluronic acid (HA) with lidocaine (3 mg/mL) for the treatment of skin depressions due to premature aging. Prior studies have demonstrated the safety and efficacy of VYC‐17.5L in nasolabial folds, lips, and radial cheek lines, but little has been published on the effectiveness of VYC17.5L for forehead contouring.
Aims
This prospective, open‐label, post‐marketing study conducted in France evaluated the effectiveness and safety of the HA injectable filler VYC‐17.5L for use in forehead contouring.
Methods
Adults (≥ 18 years) with irregularities of forehead contouring received VYC‐17.5L in the forehead on Day 1 with an optional touch‐up on Day 14. Effectiveness was assessed via investigator‐rated Global Aesthetic Improvement Scale (GAIS) of “improved” or “much improved” from baseline at month 1 (M1). Secondary endpoints included participant‐rated GAIS and FACE‐Q Satisfaction with Facial Appearance. Injection site reactions (ISRs) and adverse device effects (ADEs) were assessed throughout the study.
Results
Eighty subjects completed the study. The primary endpoint was met: 97.5% of participants showed improvement on the investigator GAIS. Participant GAIS scores were also improved. FACE‐Q scores significantly improved from baseline ( p < 0.0001) and were sustained through month 12. Most ISRs were mild or moderate and resolved in ~ 1 week. Nine subjects (11%) reported ADEs, with the majority being mild or moderate; the most common ADE was pain, which resolved in < 15 days.
Conclusion
VYC‐17.5L was well tolerated and effective for improving forehead contouring, as demonstrated by improvements in investigator‐ and participant‐rated measures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clínica Mira and Cueto, Madrid, Spain.
- Instituto Médico Miramar, Malaga, Spain.
- GRITTI Chirurgia Maxillo Facciale, Milan, Italy.
- Private Practice, Torino, Italy.
- Allergan Aesthetics, an AbbVie Company, Madrid, Spain.
- Allergan Aesthetics, an AbbVie Company, Marlow, UK.
ORCID-Profile: Fernando Urdiales Galvez
Förderung
- AbbVie
Zitieren
APA
Del Cueto, S. R., Galvez, F. U., Gritti, A., Kefalas, N., de la Guardia, C., & Kerson, G. (2025). An Evaluation of VYC ‐17. 5L for Forehead Contouring: A Prospective, Open‐Label, Post‐Marketing Study. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70093
Vancouver
Del Cueto SR, Galvez FU, Gritti A, Kefalas N, de la Guardia C, Kerson G. An Evaluation of VYC ‐17. 5L for Forehead Contouring: A Prospective, Open‐Label, Post‐Marketing Study. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70093
BibTeX
@article{DelCueto2025,
author = {Del Cueto, Sofia Ruiz and Galvez, Fernando Urdiales and Gritti, Alessandro and Kefalas, Nicola and de la Guardia, Carola and Kerson, Graeme},
title = {An Evaluation of VYC ‐17. 5L for Forehead Contouring: A Prospective, Open‐Label, Post‐Marketing Study},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.70093}
}
EUVIMED